Jemma Longley
Southampton, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Antibody based therapies in Hodgkin lymphoma.
Journal: Cancer treatment reviews
Published: August 03, 2023
HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy.
Journal: Journal of experimental & clinical cancer research : CR
Published: October 04, 2021
Personalized medicine for Hodgkin lymphoma: Mitigating toxicity while preserving cure.
Journal: Hematological oncology
Published: June 09, 2021
Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs.
Journal: Current oncology reports
Published: March 31, 2021
Options for first line therapy of Hodgkin lymphoma.
Journal: Hematological oncology
Published: June 13, 2019
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 18, 2018
Current treatment paradigms for advanced stage Hodgkin lymphoma.
Journal: British journal of haematology
Published: November 09, 2018
Should Response-Adapted Therapy Now Be the Standard of Care for Advanced Hodgkin's Lymphoma?
Journal: Current treatment options in oncology
Published: March 14, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026